Advertisement

AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk

      This activity is made possible by an unrestricted educational grant from Pfizer , New York, New York, and is based on a meeting held on September 4, 2008, and subsequent discussions among the authors through March 18, 2010.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Gossel TA. OTC NSAIDs: New Considerations and Options in Treating Osteoarthritis Pain in the Pharmacy Setting. New Hyde Park, New York: The CE Solution.

        • American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs
        Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper.
        Arthritis Rheum. 2008; 59: 1058-1073
        • Singh G.
        • Fort J.G.
        • Goldstein J.L.
        • Levy R.A.
        • Hanrahan P.S.
        • Bello A.E.
        • Andrade-Ortega L.
        • Wallemark C.
        • Agrawal N.M.
        • Eisen G.M.
        • Stenson W.F.
        • Triadafilopoulos G.
        • SUCCESS-I Investigators
        Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study.
        Am J Med. 2006; 119: 255-266
        • Bombardieri S.
        • Cattani P.
        • Ciabattoni G.
        • Di Munno O.
        • Pasero G.
        • Patrono C.
        • Pinca E.
        • Pugliese F.
        The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of sterioidal and nonsterioidal anti-inflammatory drugs.
        Br J Pharmacol. 1981; 73: 893-901
        • Peplow P.V.
        Properties and actions of non-steroidal anti-inflammatory drugs, including their effects on prostaglandin and macromolecular synthesis.
        Prostaglandins Leukot Essent Fatty Acids. 1988; 33: 239-252
        • Farkouh M.E.
        • Greenberg B.P.
        An evidence-based review of the cardiovascular risks of nonstreroidal anti-inflammatory drugs.
        Am J Cardiol. 2009; 103: 1227-1237
        • Gladding P.A.
        • Webster M.W.I.
        • Farrell H.B.
        • Zeng I.S.L.
        • Park R.
        • Ruijne N.
        The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.
        Am J Cardiol. 2008; 101: 1060-1063
        • Gurbel P.A.
        • Bliden K.P.
        • DiChiara J.
        • Newcomer J.
        • Weng W.
        • Neerchal N.K.
        • Gesheff T.
        • Chaganti S.K.
        • Etherington A.
        • Tantry U.S.
        Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
        Circulation. 2007; 115: 3156-3164
        • Scheiman J.
        Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
        Gastroenterol Clin North Am. 2009; 38: 305-314
        • Antman E.M.
        • Bennett J.S.
        • Daugherty A.
        • Furberg C.
        • Roberts H.
        • Taubert K.A.
        Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.
        Circulation. 2007; 115: 1634-1642
        • Burke A.
        • Smyth E.
        • FitzGerald G.A.
        Analgesic-antipyretic agents: pharmacotherapy of gout.
        in: Brunton L.L. Lazo J.S. Parker K.L. The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, New York, New York2006: 671-715
        • Huerta C.
        • Castellsague J.
        • Valas-Lorenzo C.
        • García Rodríguez L.A.
        Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.
        Am J Kidney Dis. 2005; 45: 531-539
        • Moyad M.A.
        Review of potential risk factors for kidney (renal cell) cancer.
        Semin Urol Oncol. 2001; 19: 280-293
        • Solomon D.H.
        • Avorn J.
        • Sturmer T.
        • Glynn R.J.
        • Mogun H.
        • Schneeweiss S.
        Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high risk subgroups and time course of risk.
        Arthritis Rheum. 2006; 54: 1378-1389
        • Graham D.J.
        • Campen D.
        • Hui R.
        • Spence M.
        • Cheetham C.
        • Levy G.
        • Shoor S.
        • Ray W.A.
        Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
        Lancet. 2005; 365: 475-481
        • Haag M.D.M.
        • Bos M.J.
        • Hofman A.
        • Koudstaal P.J.
        • Breteler M.M.B.
        • Stricker B.H.C.
        Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
        Arch Intern Med. 2008; 168: 1219-1224
        • Bombardier C.
        • Laine L.
        • Reicin A.
        • Shapiro D.
        • Burgos-Vargas R.
        • Davis B.
        • Day R.
        • Ferraz M.B.
        • Hawkey C.J.
        • Hochberg M.C.
        • Kvien T.K.
        • Schnitzer T.J.
        • VIGOR Study Group
        Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
        N Engl J Med. 2000; 343: 1520-1528
        • Levesque L.E.
        • Brophy J.M.
        • Zhang B.
        The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.
        Ann Intern Med. 2005; 142: 481-489
        • Kerr D.J.
        • Dunn J.A.
        • Langman M.J.
        • Smith J.L.
        • Midgley R.S.
        • Stanley A.
        • Stokes J.C.
        • Julier P.
        • Iveson C.
        • Duvvuri R.
        • McConkey C.C.
        • VIGOR Trial Group
        Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
        N Engl J Med. 2007; 357: 360-369
        • Mamdani M.
        • Juurlink D.N.
        • Lee D.S.
        • Rochon P.A.
        • Kopp A.
        • Naglie G.
        • Austin P.C.
        • Laupacis A.
        • Stukel T.A.
        Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
        Lancet. 2004; 363: 1751-1756
        • Crofford L.J.
        • Lipsky P.E.
        • Brooks P.
        • Abramson S.B.
        • Simon L.S.
        • Van de Putte L.B.A.
        Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.
        Arthritis Rheum. 2000; 43: 4-13
        • Silverstein F.E.
        • Faich G.
        • Goldstein J.L.
        • Simon L.S.
        • Pincus T.
        • Whelton A.
        • Makuch R.
        • Eisen G.
        • Agrawal N.M.
        • Stenson W.F.
        • Burr A.M.
        • Zhao W.W.
        • Kent J.D.
        • Lefkowith J.B.
        • Verburg K.M.
        • Geis G.S.
        Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.
        JAMA. 2000; 284: 1247-1255
        • Antiplatelet Trialists' Collaboration
        Collaborative overview of randomized trials of antiplatelet treatment.
        BMJ. 1994; 308: 81-106
        • Eidelman R.S.
        • Herbert P.R.
        • Weisman S.M.
        • Hennekens C.H.
        An update on aspirin in the primary prevention of cardiovascular disease.
        Arch Intern Med. 2003; 163: 2006-2010
        • Catella-Lawson F.
        • Reilly M.P.
        • Kapoor S.C.
        • Cucchiara A.J.
        • DeMarco S.
        • Tournier B.
        • Vyas S.N.
        • FitzGerald G.A.
        Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
        N Engl J Med. 2001; 345: 1809-1817
        • Targownik L.E.
        • Metge C.J.
        • Leung S.
        • Chateau D.G.
        The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
        Gastroenterology. 2008; 134: 937-944
        • Oitate M.
        • Hirota T.
        • Koyama K.
        • Inoue S.
        • Kawai K.
        • Ikeda T.
        Covalent binding of radioactivity from 14 C rofecoxib, but not 14 C celecoxib or 14 C CS-706, to the arterial elastic of rats.
        JPET. 2006; 34: 1417-1422
        • Oitate M.
        • Hirota T.
        • Takahashi M.
        • Murai T.
        • Miura S.
        • Senoo A.
        • Hosokawa T.
        • Oonishi T.
        • Ikeda T.
        Mechanism for covalent binding of rofecoxib to elastin of rat aorta.
        JPET. 2007; 320: 1195-1203
        • Steffel J.
        • Hermann M.
        • Greutert H.
        • Gay S.
        • Luscher T.F.
        • Ruschitzka F.
        • Tanner F.C.
        Celecoxib decreases endothelial tissue factor expression through inhibition of c-jun terminal NH 2 kinase phosphorylation.
        Circulation. 2005; 111: 1685-1689
        • Chandrasekharan N.V.
        • Dai H.
        • Roos L.T.
        • Evanson N.K.
        • Tomsik J.
        • Elton T.S.
        • Simmons D.L.
        COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.
        Proc Natl Acad Sci U S A. 2002; 99: 13926-13931
        • Botting R.M.
        Mechanism of action of acetaminophen: is there a cyclooxygenase 3?.
        Clin Infect Dis. 2000; 31: 8202-8210
        • Flower R.J.
        • Vane J.R.
        Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol).
        Nature (London). 1972; 240: 410-411
        • Laine L.
        • White W.B.
        • Rostom A.
        • Hochberg M.
        COX-2 selective inhibitors in the treatment of osteoarthritis.
        Semin Arthritis Rheum. 2007; 38: 165-187
        • Hogestatt E.D.
        • Jönsson B.A.
        • Ermund A.
        • Andersson D.A.
        • Björk H.
        • Alexander J.P.
        • Cravatt B.F.
        • Basbaum A.I.
        • Zygmunt P.M.
        Conversion of acetaminophen to the bioactive N-acyphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic conjunction in the nervous system.
        J Biol Chem. 2005; 280: 21405-21412
        • Solomon S.D.
        • Pfeffer M.A.
        • McMurray J.J.
        • Fowler R.
        • Finn P.
        • Levin B.Bernard Levin
        • Eagle C.
        • Hawk E.
        • Lechuga M.
        • Zauber A.G.
        • Bertagnolli M.M.
        • Arber N.
        • Wittes J.
        • APC and PreSAP Trial Investigators
        Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
        Circulation. 2006; 114: 1028-1035
        • Solomon S.D.
        • McMurray J.J.
        • Pfeffer M.A.
        • Wittes J.
        • Fowler R.
        • Finn P.
        • Anderson W.F.
        • Zauber A.G.
        • Hawk E.
        • Bertagnolli M.M.
        • Arber N.
        • Adenoma Prevention With Celecoxib (A.P.C.) Study Investigators
        Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
        N Engl J Med. 2005; 352: 1071-1080
        • ADAPT Research Group
        Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).
        PLoS Clin Trials. 2006; 1: e33
        • Moskowitz R.W.
        Osteoarthritis: simple analgesics versus nonsteroidal anti-inflammatory drugs.
        J Rheumatol. 2001; 28: 932-934
        • Bresalier R.S.
        • Sandler R.S.
        • Quan H.
        • Bolognese J.A.
        • Oxenius B.
        • Horgan K.
        • Lines C.
        • Riddell R.
        • Morton D.
        • Lanas A.
        • Konstam M.A.
        • Baron J.A.
        • Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
        Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
        N Engl J Med. 2005; 352: 1092-1102
        • Cox E.R.
        • Frisse M.
        • Behm A.
        • Fariman K.A.
        Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users.
        Arch Intern Med. 2004; 164: 1243-1246
        • Solomon D.H.
        • Karlson E.W.
        • Rimm E.B.
        • Cannuscio C.C.
        • Mandl L.A.
        • Manson J.E.
        • Stampfer M.J.
        • Curhan G.C.
        Cardiovascular morbidity and mortality in women associated with rheumatoid arthritis.
        Circulation. 2003; 107: 1303-1307
        • Hippisley-Cox J.
        • Coupland C.
        Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
        BMJ. 2005; 330 (1366–1342)
        • Cannon C.P.
        • Curtis S.P.
        • FitzGerald G.A.
        • Krum H.
        • Kaur A.
        • Bolognese J.A.
        • Reicin A.S.
        • Bombardier C.
        • Weinblatt M.E.
        • van der Heijde D.
        • Erdmann E.
        • Laine L.
        • MEDAL Steering Committee
        Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) programme: a randomised comparison.
        Lancet. 2006; 368: 1771-1781
        • Farkouh M.E.
        • Kirshner H.
        • Harrington R.A.
        • Ruland S.D.
        • Verheugt F.W.A.
        • Schnitzer T.J.
        • Burmester G.R.
        • Mysler E.
        • Hochberg M.C.
        • Doherty M.
        • Ehrsam E.
        • Gitton X.
        • Krammer G.
        • Mellein B.
        • Gimona A.
        • Matchaba P.
        • Hawkey C.J.
        • Chesebro J.H.
        Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
        Lancet. 2004; 364: 675-684
        • Roumie C.L.
        • Mitchel Jr, E.F.
        • Kaltenbach L.
        • Arbogast P.G.
        • Gideon P.
        • Griffin M.R.
        Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke.
        Stroke. 2008; 39: 2037-2045
        • Bak S.
        • Andersen M.
        • Tsiropoulous I.
        • Garcia Rodriguez L.A.
        • Hallas J.
        • Christensen K.
        • Gaist D.
        Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study.
        Stroke. 2003; 34: 379-386
        • White W.B.
        Defining the problem of treating the patient with hypertension and arthritis pain.
        Am J Med. 2009; 122: S3-S9
        • Clive D.M.
        • Stoff J.S.
        Renal syndromes associated with nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1984; 310: 563-572
        • Whelton A.
        • Hamilton C.W.
        Nonsteroidal anti-inflammatory drugs: effects on kidney function.
        J Clin Pharmacol. 1991; 31: 588-598
        • Harris R.C.
        • Breyer M.D.
        Arachidonic acid metabolites and the kidney.
        in: Brenner B.M. Brenner and Rector's The Kidney. 7th ed. W. B. Saunders, St. Louis, Missouri2004: 727-761
        • Evans J.M.
        • McGregor E.
        • McMahon A.D.
        • McGilchrist M.M.
        • Jones M.C.
        • White G.
        • McDevitt D.G.
        • MacDonald T.M.
        Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure.
        Q J Med. 1995; 88: 551-557
        • Perez Gutthann S.
        • García Rodríguez L.A.
        • Raiford D.S.
        • Duque Oliart A.
        • Ris Romeu J.
        Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure.
        Arch Intern Med. 1996; 156: 2433-2439
        • Griffin M.R.
        • Yared A.
        • Ray W.A.
        Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons.
        Am J Epidemiol. 2000; 151: 488-496
        • Hermann M.
        • Camici G.
        • Fratton A.
        • Hurlimann D.
        • Tanner F.C.
        • Hellerman J.P.
        • Fiedler M.
        • Thiery J.
        • Neidhart M.
        • Gay R.E.
        • Gay S.
        • Lüscher T.F.
        • Ruschitzka F.
        Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
        Circulation. 2003; 108: 2308-2311
        • Whelton A.
        • White W.B.
        • Bello A.E.
        • Puma J.A.
        • Fort J.G.
        • SUCCESS-VII Investigators
        Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis.
        Am J Cardiol. 2002; 90: 959-963
        • White W.B.
        • Schnitzer T.J.
        • Fleming R.
        • Duquesroix B.
        • Beekman M.
        Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.
        Am J Cardiol. 2009; 104: 840-845
        • Gilslason G.H.
        • Rasmussen J.N.
        • Abildstrom S.Z.
        • Schramm T.K.
        • Hansen M.L.
        • Fosbol E.L.
        • Sorenson R.
        • Folke F.
        • Buch P.
        • Gadsboll N.
        • Rasmussen S.
        • Poulsen H.E.
        • Køber L.
        • Madsen M.
        • Torp-Pedersen C.
        Increased mortality and cardiovascular mortality associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.
        Arch Intern Med. 2009; 169: 141-149
        • Whelton A.
        • Schulman G.
        • Wallemark C.
        • Drower E.J.
        • Isakson P.C.
        • Verburg K.M.
        • Geis S.
        Effects of celecoxib and naproxen on renal function in the elderly.
        Arch Intern Med. 2000; 160: 1465-1470
        • Beck C.H.
        Changes in renal function with aging.
        Clin Geriatr Med. 1998; 14: 199-209
        • Brater D.C.
        Anti-inflammatory agents and renal function.
        Semin Arthritis Rheum. 2002; 32: S33-S42
        • Cohen S.M.
        • Shirai T.
        • Steineck G.
        Epidemiology and etiology of premalignant and malignant urothelial changes.
        Scand J Urol Nephrol Suppl. 2000; 205: 105-115
        • Graham G.G.
        • Graham R.I.
        • Day R.O.
        Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib, and acetaminophen (paracetamol).
        Curr Pharm Des. 2002; 2: 1063-1075
        • Zhang J.
        • Ding E.L.
        • Song Y.
        Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
        JAMA. 2006; 296: 1619-1632
        • Garcia Rodriguez L.A.
        • Jick H.
        Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.
        Lancet. 1994; 343: 769-772
        • Hennekens C.H.
        • Dyken M.L.
        • Fuster V.
        Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
        Circulation. 1997; 96: 2751-2753
        • United States Preventive Services Task Force
        Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2009; 150: 396-404
        • United States Preventive Services Task Force
        Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2009; 150: 405-410
        • FitzGerald G.A.
        • Patrono C.
        The coxibs, selective inhibitors of cyclooxygenase-2.
        N Engl J Med. 2001; 345: 433-442
        • MacDonald T.M.
        • Wei L.
        Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?.
        Basic Clin Pharmacol Toxicol. 2006; 98: 275-280
        • Wilner K.D.
        • Rushing M.
        • Walden C.
        • Adler R.
        • Eskra J.
        • Noveck R.
        • Vargas R.
        Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.
        J Clin Pharmacol. 2002; 42: 1027-1030
        • Kimmel S.E.
        • Berlin J.A.
        • Reilly M.
        • Jaskowiak J.
        • Kishel L.
        • Strom B.L.
        Lower myocardial infarction risk amongst current users of non-aspirin nonsteroidal anti-inflammatory medications [abstract].
        J Am Coll Cardiol. 2002; 39: 318A
        • FitzGerald G.A.
        Parsing an enigma: the pharmacodynamics of aspirin resistance.
        Lancet. 2003; 361: 573-574
        • Ray W.A.
        • Stein C.M.
        • Hall K.
        • Daugherty J.R.
        • Griffin M.R.
        Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
        Lancet. 2002; 359: 118-123
        • Capone M.L.
        • Sciulli M.G.
        • Tacconelli S.
        • Grana M.
        • Ricciotti E.
        • Renda G.
        • Di Gregorio P.
        • Merciaro G.
        • Patrignani P.
        Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
        J Am Coll Cardiol. 2005; 45: 1295-1301
        • Rowlinson S.W.
        • Kiefer J.R.
        • Prusakiewicz J.J.
        • Pawlitz J.L.
        • Kozak K.R.
        • Kalgutkar A.S.
        • Stallings W.C.
        • Kurumbail R.G.
        • Marnett L.J.
        A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.
        J Biol Chem. 2003; 278: 45763-45769
        • United States Food and Drug Administration
        Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk.
        J Pain Palliat Care Pharmacother. 2005; 19: 83-97
        • ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use
        A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
        Circulation. 2008; 118: 1894-1909
        • Gislason G.H.
        • Jacobsen S.
        • Rasmussen J.N.
        • Rasmussen S.
        • Buch P.
        • Friberg J.
        • Schramm T.K.
        • Abildstrom S.Z.
        • Køber L.
        • Madsen M.
        • Torp-Pedersen C.
        Risk of death or reinfarction associated with use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
        Circulation. 2006; 113: 2906-2913
        • Nussmeirer N.A.
        • Whelton A.A.
        • Brown M.T.
        • Langford R.M.
        • Hoeft A.
        • Parlow J.L.
        • Boyce S.W.
        • Verburg K.M.
        Complications of the COX-2 inhibitors parecoxib and celecoxib after cardiac surgery.
        N Engl J Med. 2005; 352: 1081-1091
        • Julius S.
        • Kjeldsen S.E.
        • Weber M.
        • Brunner H.R.
        • Ekman S.
        • Hansson L.
        • Hua T.
        • Laragh J.
        • McInnes G.T.
        • Mitchell L.
        • Plat F.
        • Schork A.
        • Smith B.
        • Zanchetti A.
        • VALUE Trial Group
        Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
        Lancet. 2004; 363: 2022-2031
        • Gaziano J.M.
        Nonnarcotic analgesics and hypertension.
        Am J Cardiol. 2006; 97: 10E-16E
        • Johnson A.G.
        • Nguyen T.V.
        • Day R.O.
        Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.
        Ann Intern Med. 1994; 121: 289-300
        • Pope J.E.
        • Anderson J.J.
        • Felson D.T.
        A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure.
        Arch Intern Med. 1993; 153: 477-484
        • White W.B.
        Cardiovascular effects of the cyclooxygenase inhibitors.
        Hypertension. 2007; 49: 408-418
        • Chenevard R.
        • Hürlimann D.
        • Béchir M.
        • Enseleit F.
        • Spieker L.
        • Hermann M.
        • Riesen W.
        • Gay S.
        • Gay R.E.
        • Neidhart M.
        • Michel B.
        • Lüscher T.F.
        • Noll G.
        • Ruschitzka F.
        Selective COX-2 inhibition improves endothelial function in coronary artery disease.
        Circulation. 2003; 107: 405-409
        • Helin-Salmivaara A.
        • Virtanen A.
        • Vesealanin R.
        • Gronroos J.M.
        • Klaukka T.
        • Idanpaan-Heikkila J.E.
        • Huupponen R.
        NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.
        Eur Heart J. 2006; 27: 1657-1663
        • American Diabetes Association
        Standards of medical care for patients with diabetes mellitus (position statement).
        Diabetes Care. 2001; 24: S33-S43
        • Bakris G.L.
        • Williams M.
        • Dworkin L.
        • Elliott W.J.
        • Epstein M.
        • Toto R.
        • Tuttle K.
        • Douglas J.
        • Hsueh W.
        • Sowers J.
        • National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group
        Preserving renal function in adults with hypertension and diabetes: a consensus approach.
        Am J Kidney Dis. 2000; 36: 646-661
        • Antithrombotic Trialists' Collaboration
        Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Sorenson H.T.
        • Mellemkjaer L.
        • Blot W.J.
        • Nielsen G.L.
        • Steffensen F.H.
        • McLaughlin J.K.
        • Olsen J.H.
        Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
        Am J Gastroenterol. 2000; 95: 2218-2224
        • Chan F.K.L.
        • Wong V.W.
        • Suen B.Y.
        • Wu J.C.
        • Ching J.Y.
        • Hung L.C.
        • Hui A.J.
        • Sun Leung V.K.
        • Yan Lee V.W.
        • Lai L.H.
        • Hung Wong G.L.
        • Lai Chow D.K.
        • To K.F.
        • Leung W.K.
        • Yan Chiu P.W.
        • Lee Y.T.
        • Wong Lau J.Y.
        • Yuen Chan H.L.
        • Wai Ng E.K.
        • Yiu Sung J.J.
        Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
        Lancet. 2007; 369: 1621-1626
        • Rahme E.
        • Barkun A.N.
        • Toubouti Y.
        • Scalera A.
        • Rochon S.
        • Lelorier J.
        Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?.
        Arthritis Rheum. 2007; 57: 748-755
        • Aneja A.
        • Farkouh M.E.
        Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?.
        Ther Adv Cardiovasc Dis. 2008; 2: 53-66
        • Schneider V.
        • Levesque L.E.
        • Zhang B.
        • Hutchinson T.
        • Brophy J.M.
        Association of selective and conventional nonsteroidal antiiflammatory drugs with acute renal failure: a population-based, nested case-control study.
        Am J Epidemiol. 2006; 164: 881-889
        • Epstein M.
        Aging and the kidney.
        J Am Soc Nephrol. 1996; 7: 1106-1122
        • Moore R.A.
        • Derry S.
        • McQuay H.J.
        • Paling J.
        What do we know about communicating risk?.
        Arthritis Res Ther. 2005; 10 (Accessed on April 28): R20
        • Scheiman J.M.
        • Fendrick A.M.
        Summing the risk of NSAID therapy.
        Lancet. 2007; 369: 1580-1581
        • Lauer M.S.
        Aspirin for primary prevention of coronary events.
        N Engl J Med. 2002; 346: 1468
        • Strand V.
        Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?.
        Lancet. 2007; 370: 2138-2151
        • McGetigan P.
        • Henry D.
        Cardiovascular risk and inhibition of cyclooxygenase.
        JAMA. 2006; 296: 1653-1656
        • McGettigan P.
        • Han P.
        • Jones L.
        • Whitaker D.
        • Henry D.
        Selective cox-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
        Br J Clin Pharmacol. 2008; 65: 927-934
        • Patrono C.
        • Rocca B.
        Nonsteroidal antiinflammatory drugs: past, present, and future.
        Pharmacol Res. 2009; 59: 285-289
        • Lohmander L.S.
        • McKeith D.
        • Svensson O.
        • Malmenas M.
        • Bolin L.
        • Kalla A.
        • Genti G.
        • Szechinski J.
        • Ramos-Remus C.
        • STAR Multinational Study Group
        A randomized, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
        Ann Rheum Dis. 2005; 64: 449-456
        • Schnitzer T.J.
        • Kivitz A.J.
        • Lipetz R.S.
        • Sanders N.
        • Hee A.
        Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee.
        Arthritis Rheum. 2005; 53: 827-837
        • United States Food and Drug Administration
        Concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin.
        (Accessed on January 4)
        • Insel P.
        Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout.
        in: Hardman J.G. Gilman A.G. Limbird L.E. Goodman's & Gilman's The Pharmaceutical Basis of Therapeutics. 5th ed. Mcgraw-Hill, New York1996: 617-643
        • Lanza F.L.
        A guideline for treatment and prevention of NSAID-induced ulcers.
        Am J Gastroenterol. 1998; 93: 2037-2046
        • Altman R.D.
        Recommendations for the medical management of osteoarthritis of the hip and knee; 2000 update.
        Arthritis Rheum. 2000; 43: 1905-1915
        • Cheema A.
        Should people on aspirin avoid ibuprofen?.
        Cardiol in Review. 2004; 12: 174-176
        • Cryer B.
        • Berlin R.G.
        • Cooper S.A.
        • Hsu C.
        • Wason S.
        Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers.
        Clin Ther. 2005; 27: 185-191
        • Curtis J.P.
        • Wang Y.
        • Portnay E.L.
        • Masoudi F.A.
        • Havranek E.P.
        • Krumholz H.M.
        Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study.
        BMJ. 2003; 327: 1322-1333
        • Rodriguez L.A.G.
        Nonsteroidal antiinflammatory drugs and the risk of myocardialinfarction in the general population.
        Circulation. 2004; 109: 3000-3006
        • Hudson M.
        • et al.
        Anti-inflammatory drugs are associated with a decreased risk of recurrent acute myocardial infarction in patients on aspirin.
        Arthritis Rheum. 2002; 46 (Abstract): S617
        • Patel T.N.
        • Goldberg K.C.
        Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction.
        Arch Intern Med. 2004; 164: 852-856
        • MacDonald T.M.
        • Wei L.
        Effect of ibuprofen on cardioprotective effect of aspirin.
        Lancet. 2003; 361: 573-574
        • Kurth T.
        • Glynn J.
        • Walker A.M.
        • Chan K.A.
        • Buring J.E.
        • Hennekens C.H.
        • Michael Gaziano J.M.
        Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
        Circulation. 2003; 108: 1191-1195
        • Kimmel S.E.
        • Berlin J.A.
        • Reilly M.
        • Jaskowiak J.
        • Kishel L.
        • Chittams J.
        • Strom B.L.
        The effects of nonselective non-aspirin non-steroidal anti inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin.
        J Am Coll Cardiol. 2004; 43: 985-990

      Linked Article